SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending downwards after a mixed earnings report, with investors focusing on revenue miss and increased capital expenditures despite strong cloud growth. The community is actively discussing the implications of Oracle's AI strategy, its debt levels, and potential impacts on the broader AI market and related stocks. Some traders speculate on a potential bounce or further declines, while others question the long-term viability of Oracle's approach.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid discussions of a potential market downturn despite the Fed's decision to hold interest rates steady, with community members debating whether this is a bull trap or a sign of further gains. Mixed sentiment prevails as some traders point to weak earnings from key tech companies like Oracle as a harbinger of a broader correction, while others remain optimistic about a continued rally fueled by AI and potential QE measures. The conversation is heavily focused on interpreting the Fed's actions and their implications for inflation, bond yields, and the overall market trajectory.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as the community discusses a potential partnership with Elon Musk's xAI, particularly regarding the build-out of the 'Colossus 2' AI supercomputer, which could significantly boost revenue. Community members are speculating on potential revenue impact and upgrades, while also debating valuation concerns and the company's historical performance. Sentiment is mixed, with some highlighting the potential for a short squeeze and others expressing caution.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing active discussion as traders digest recent market movements and speculate on future direction. Community members are focused on key support and resistance levels, with some anticipating a pullback while others maintain a bullish outlook. Oracle's earnings and potential AI impacts are also influencing the conversation around QQQ's trajectory.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors discuss its AI strategy and recent market performance, with some expressing concerns about its correlation to Oracle's performance and others pointing to potential overbought conditions. The community is actively debating whether the company is currently undervalued, especially given its investments in AI and cloud infrastructure, and if it can reach $500 again soon. Some traders are closely watching technical indicators for potential entry points, while others express frustration with its perceived underperformance relative to other tech giants.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to its low float and recent surge, sparking discussions about potential short squeezes and further upside. The community is closely watching for news from the upcoming Emerging Growth Conference and any updates regarding the company's shift towards AI/GPU infrastructure. With increased power capacity and hosting services, MIGI's transformation from a pure miner to a broader digital infrastructure player is also a key talking point.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to its impressive gains, leading to community discussions around a potential short squeeze and comparisons to similar high-flying stocks. The stock's low float and high short interest are key talking points, with many anticipating further upward movement. Some traders are expressing caution, highlighting the risks associated with chasing highly volatile stocks.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as the community discusses a strategic alliance with Tata Electronics to bolster India's semiconductor ecosystem. Despite positive news, some investors express concerns about outsourcing and potential impacts on domestic manufacturing. Community members are actively debating Intel's potential for growth amid evolving market dynamics and government policies.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to its upcoming inclusion in the S&P 500, spurring a significant rally and debate among traders about its valuation. Community discussion revolves around whether the stock's surge is justified by fundamentals or driven by market mechanics and potential short squeezes, with some viewing it as a highly manipulated meme stock. Despite concerns about the company's debt and business practices, the stock continues to climb, driven by momentum and options trading.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses recent price movement and potential catalysts, including the upcoming Fed rate decision. Community members are debating whether recent price dips represent buying opportunities or reflect broader market manipulation, with some expressing frustration and others maintaining long-term bullish sentiment. Influencers and analysts predictions, particularly around year-end price targets, are being heavily scrutinized amid ongoing market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Brelovitug is a late-stage experimental drug being studied for chronic hepatitis delta virus infection.&nbsp;</li><li>The transaction with Bluejay is expected to close in the first quarter of 2026.</li><li>Mirum said it had secured $200 million through a private placement to be used to fund clinical development and commercial activities following the proposed acquisition.</li></ul>Shares of Mirum Pharmaceuticals, Inc. (MIRM) fell as much as 5% on Monday morning after the company announced that it has agreed to buy privately held Bluejay Therapeutics in a deal worth up to $820 million.The move is aimed at advancing the company in rare disease by adding Bluejay’s Brelovitug to its portfolio. Brelovitug is a late-stage experimental drug being studied for chronic hepatitis delta virus (HDV) infection, a most severe form of viral hepatitis in which nearly half of those affected progress to liver-related death within 10 years of diagnosis.<h2 class="st-heading-2">Deal Terms</h2>Under the deal, Mirum has <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251208788160/en/Mirum-Pharmaceuticals-Enters-into-Definitive-Agreement-to-Acquire-Bluejay-Therapeutics-Expanding-Global-Leadership-in-Rare-Disease">agreed</a> to acquire all outstanding shares of Bluejay for $250 million in cash and $370 million in Mirum common stock, in addition to potential sales-based milestone payments of up to $200 million in cash.The transaction with Bluejay is expected to close in the first quarter of 2026, subject to regulatory approval and other customary closing conditions, the company added.<h2 class="st-heading-2">About the Liver Drug&nbsp;</h2>Brelovitug is currently in late stage trials for HDV. In mid-stage trials, Brelovitug demonstrated strong antiviral activity in HDV and improvements in liver enzyme levels and a favorable safety profile.Mirum said on Monday that it expects top-line data from the late-stage trial in the second half of 2026, with application to the FDA for potential approval slated for 2027.Mirum also said that it will evaluate strategic options for Bluejay’s additional investigational programs after closing of the deal.<h2 class="st-heading-2">Placement Announcement</h2>Mirum on Monday also said that it has entered into a definitive agreement with a syndicate of existing and new healthcare investors, for the sale of Mirum common stock and pre-funded warrants, in a private placement.The private placement is expected to result in gross proceeds of $200 million which will be used to fund clinical development and commercial activities following the proposed acquisition, the company said.<h2 class="st-heading-2">Expert Take</h2>Cantor Fitzgerald subsequently raised the price target on Mirum to $130 from $95, while keeping an ‘Overweight’ rating on the shares. The new price target represents a potential upside of about 90% from the stock’s closing price on Friday.Cantor opined that Mirum’s proposed acquisition of Bluejay under the agreed-upon terms is a “steal.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MIRM">MIRM</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:586/57;" src="data:image/png;base64,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" alt="MIRM’s Sentiment Meter and Message Volume as of 11:13 a.m. ET on Dec. 08, 2025 | Source: Stocktwits" width="586" height="57"><figcaption>MIRM’s Sentiment Meter and Message Volume as of 11:13 a.m. ET on Dec. 08, 2025 | Source: Stocktwits</figcaption></figure>MIRM stock has gained 64% this year and by about 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apple-chip-chief-reportedly-dismisses-concerns-about-exit/cLIYHDjREmk">Apple Chip Chief Reportedly Dismisses Concerns About Exit: ‘I Love My Job’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal'

The move is aimed at advancing the company in rare disease by adding Bluejay’s Brelovitug to its portfolio.

Equity

The move is aimed at advancing the company in rare disease by adding Bluejay’s Brelovitug to its portfolio.


<ul class="summary-bullets"><li>The company said that the fraud impacted the company’s financial statement in multiple ways and anticipates filing new financial statements shortly.</li><li>An executive said that the cost of the Lugano fraud will, by a wide margin, represent the most significant loss Cody has experienced since its inception.</li><li>Retail investors, analysts await restated financial statements.</li></ul>Shares of Compass Diversified (CODI) fell a steep 18% on Friday after the company announced it must restate its financial results for fiscal year 2022 to 2024 after its probe led to findings of fraud at its subsidiary Lugano.The company has removed financial information for the years 2022 to 2024 from its website, citing non-reliance.“I want to begin by saying that this has been, without question, the most challenging period in Cody's history,” CEO Elias Sabo said in a call. He further added that the fraud at Lugano was “pervasive, complex and isolated to that business.”<h2 class="st-heading-2">Probe And Findings</h2>Compass Diversified announced in early May that its audit committee has initiated an investigation into the financing, accounting, and inventory practices of Lugano. The subsidiary’s CEO Moti Ferder subsequently resigned from the company without any severance compensation.As per Sabo, Ferder and his family have fled the U.S. and permanently relocated to Israel. The audit committee probe has concluded and discovered “deliberate and systemic fraud,” he added.“The former Lugano CEO engaged in a scheme to significantly overstate Lugano's sales and profits, misrepresent the existence and value of Lugano's inventory, and keep potential financial liabilities off Lugano's books and records. His efforts to hide his fraud were extensive,” Sabo said. He added that Ferder created fake sales transactions to inflate Lugano’s reported revenues, claimed inventory that either didn't exist or didn’t belong to Lugano and entered numerous financing agreements with third parties that he kept off the company’s balance sheet.<h2 class="st-heading-2">Impact Of The Fraud</h2>CODI is a holding company that acquires and actively manages middle-market businesses. It acquired Lugano Diamonds &amp; Jewelry, Inc., a designer, manufacturer and marketer of one-of-a-kind jewelry in September 2021.The company said that the fraud impacted the company’s financial statement in multiple ways and anticipates filing new financial statements shortly. The company also intends to file its first, second, and third quarter 2025 financials over the coming weeks.“At a high level, the restatement significantly reduced our reported inventory. Consolidated inventory for 2024 was reduced by greater than $375 million, or nearly 40%...further, Lugano's revenue declined by more than 85% from previously reported levels following the removal of the fraudulent revenue,” a company executive said.Lugano filed for Chapter 11 protection under the U.S. Bankruptcy Code on November 16. “Regardless of what we ultimately recover from Lugano bankruptcy, the cost of the Lugano fraud will, by a wide margin, represent the most significant loss Cody has experienced since its inception,” the executive added.<h2 class="st-heading-2">Analyst Take</h2>According to William Blair, who has an ‘Outperform’ rating on the shares, Compass Diversified is worth at least $10 per share excluding Lugano. The firm said that it now awaits the restated financials.Blair's "back-of-the-envelope" estimate suggests Compass would need to raise about $500 million to reach its target leverage. Excluding Lugano, the company's 2025 subsidiary core profit results are tracking in line with expectations of mid-single-digit growth to $330 million-$360 million, the firm added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around Lugano jumped from ‘Neutral’ to ‘Bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user said that they will stick with the company for now and highlighted that the company’s other subsidiaries seem to be doing well and expressed anticipation for restated financials. &nbsp;<stembedurl>https://stocktwits.com/MplsBarry/message/638306243</stembedurl>Another slammed the company management for failing to identify the fraud at Lugano earlier.<stembedurl>https://stocktwits.com/SnapCrackleStop/message/638278242</stembedurl><a href="https://stocktwits.com/symbol/CODI">CODI stock</a> has dropped 74% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/new-york-times-sues-perplexity-ai-over-unauthorized-content-use-what-does-the-lawsuit-say/cLISBqyREko">New York Times Sues Perplexity AI Over Unauthorized Content Use: What Does The Lawsuit Say?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Compass Diversified Stock Plunges On ‘Most Significant Loss’ After Fraud Forces Removal Of Three Years Of Financials

The company has removed financial information for the years 2022 to 2024 from its website, citing non-reliance. 

 A window display of actress Sydney Sweeney is seen on a window of an American Eagle store on August 01, 2025 in New York City. 

American Eagle's Gen Z Playbook Is Working — Sydney Sweeney And Travis Kelce Might Only Be The Opening Act

AEO appears to have gotten its brand marketing right, and the additional expense on its balance sheet to fuel celebrity partnerships is paying off.

<ul class="summary-bullets"><li>Archer is looking to pursue both defense and commercial opportunities with its aircrafts.</li><li>The company first announced its intention to build a military aircraft through a partnership with Anduril in December 2024.</li><li>A Stocktwits user said that they are bullish on the stock but want to see material results and flight tests.</li></ul>Shares of Archer Aviation Inc. (ACHR) jumped 3% on Tuesday after the company announced an exclusive collaboration with California-headquartered Karem Aircraft aimed at gaining access to the latter’s military grade technology.Archer <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251202660206/en/Archer-and-Karem-Aircraft-Announce-Exclusive-Collaboration-to-Utilize-Military-Grade-Rotor-Technology-on-Archers-Next-Generation-Dual-Use-VTOL-Aircraft">said</a> that the collaboration is aimed at accessing privately-held Karem’s military-grade rotor and tiltrotor technologies for integration into Archer’s next-generation autonomous, hybrid-propulsion VTOL aircraft. The company is looking to pursue both defense and commercial opportunities with its aircrafts.<h2 class="st-heading-2">Archer’s Military Aircraft Goals</h2>Archer Aviation first announced its intention to build a military aircraft through a partnership with Anduril in December 2024. Earlier this year, the company also announced two strategic acquisitions to accelerate its development.Archer acquired a patent portfolio and hired critical employees from Overair, a spin-off of Karem Aircraft. It also acquired key composite manufacturing assets and an approximately 60,000 square foot manufacturing facility from Mission Critical Composites, a specialized defense composite manufacturer in Southern California in August.The company expects the combined assets to enable an aircraft with the speed, range, payload, and low-thermal and acoustic signatures necessary for missions across contested airspace.“Karem’s military-grade rotor systems are among the most advanced Army-validated technologies in the world. Integrating them into our next-gen hybrid VTOL platform positions Archer to move faster and deliver capabilities that legacy systems simply can’t match,” said Archer CEO Adam Goldstein.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHR">ACHR</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.One user said, “less talk and more action needed from management. Where are the flight tests? Where are the new aircraft? Bullish, but it's time to show results.”<stembedurl>https://stocktwits.com/burnaboi278/message/637903665</stembedurl>Last month, Hunterbrook Capital <a href="https://stocktwits.com/news-articles/markets/equity/hunterbrook-capital-reveals-short-position-in-evtol-maker-archer-aviation/cLPMHyAREfG">revealed</a> a short position in Archer after noting that its flagship Midnight electric air taxi never flew at the 2025 Dubai Airshow.ACHR stock is down by 21% this year and up by about 5% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-us-sales-slip-in-november-on-weakening-demand-for-evs/cLIaoQuREKf">Ford US Sales Slip In November On Weakening Demand For EVs After Federal Tax Credit Expiry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Archer Aviation logo is displayed on a smartphone screen. (Photo by Cheng Xin/Getty Images)

Archer Aviation Stock Jumps On Tech Deal With Karem For Military Aircraft — Retail Seeks Tangible Progress

Archer said that the collaboration is aimed at accessing privately-held Karem’s military-grade rotor and tiltrotor technologies for integration into Archer’s next-generation autonomous, hybrid-propulsion VTOL aircraft.

<ul class="summary-bullets"><li>In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness.</li><li>The company intends to meet the FDA’s additional clinical data requirement with the HOPE-3 study and expects a review period of up to six months for the resubmitted application.</li><li>‘Pharma Bro’ Martin Shkreli announced a short position in Capricor last week.&nbsp; &nbsp;</li></ul>Capricor Therapeutics stock drew heavy retail attention on Monday as retail investors are now awaiting data from the biotechnology company’s HOPE-3 study in the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Capricor said in early November that it expects to announce results from the HOPE-3 trial in the coming weeks and within the fourth quarter. The company intends to submit an application to the U.S. Food and Drug Administration based on the study data. According to the firm, 105 DMD patients have been enrolled in the recent trial.<h2 class="st-heading-2">Capricor’s Rigged Road With Deramiocel Approval</h2>In July, the FDA refused to approve Capricor’s application for Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness and expressed the need for additional clinical data. The company intends to meet the FDA’s additional clinical data requirement with the HOPE-3 study and expects a review period of up to six months for the resubmitted application.Commercial launch preparations are underway to support market introduction in 2026, the company said in November.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:583/60;" src="data:image/png;base64,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" width="583" height="60" alt="CAPR’s Sentiment Meter and Message Volume as of 3:15 p.m. ET on Dec. 1, 2025 | Source: Stocktwits"><figcaption>CAPR’s Sentiment Meter and Message Volume as of 3:15 p.m. ET on Dec. 1, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user noted that the company’s data is the best to date despite the small sample size. However, they added that, “betting against the data without seeing it is very dangerous. As a poet once said "A little knowledge is a dangerous thing, drink deep or taset not the perian spring."<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/637821091</stembedurl>Another bearish user said, “smell bad, look a like ols [old] bad news from several biotech.”<stembedurl>https://stocktwits.com/rudazur2/message/637822514</stembedurl><h2 class="st-heading-2">Short Positions And Pessimism On Trial Data</h2>Last week, former biotech executive and businessman Martin Shkreli <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-goes-short-on-capircor-therapeutics/cL5bQHUREQS">announced</a> his short position in Capricor and opined that Deramiocel will not yield positive results in the HOPE-3 study.Shkreli highlighted concerns, including limitations in cell therapies' ability to reach target tissue and other safety issues, provided they are derived from donor hearts and are not immunoprivileged cells.He further alleged that data from the company’s previous HOPE-2 trial was not meaningful. “Note the company and the publication reported a successful PE met, but the FDA disagreed,” he said.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by 51% this year and by about 66% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/q32-bio-stock-soars-on-selling-experimental-drug-to-akeba-for-to-592-million/cLI7lHgRE0c">Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout

Capricor said in early November that it expects to announce results from the HOPE-3 trial in the coming weeks. 

The Kohl'scorporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Kohl’s Traders Just Got The CEO They Wanted — And the Stock’s Weekly Breakout Says It All

Last week, KSS stock soared nearly 60%, marking its best weekly performance this year, after Michael Bender was confirmed as full-time CEO.

<ul class="summary-bullets"><li>The postponement was to accommodate the leadership shift at the Center for Drug Evaluation and Research, the company said.&nbsp;</li><li>Vanda continues to expect the agency to decide on its application seeking approval for Tradipitant for the prevention of vomiting induced by motion by December 30.&nbsp;</li><li>The company said it has commenced discussions on the drug’s proposed labeling.</li></ul>Vanda Pharmaceuticals Inc. (VNDA) said on Friday that the U.S. Food and Drug Administration (FDA)’s re-review of the clinical hold on long-term clinical studies of Tradipitant in motion sickness has been extended.The FDA was initially expected to complete the re-review on November 26 and has since then extended it to December 5 to accommodate the leadership shift at the Center for Drug Evaluation and Research, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-provides-regulatory-update-on-tradipitant-for-motion-sickness-302627878.html">said</a>.<h2 class="st-heading-2">Fresh Dates</h2>Vanda expects the agency to decide on its application seeking approval for Tradipitant for the prevention of vomiting induced by motion by December 30, according to previous schedule.The company said it has commenced discussions on the drug’s proposed labeling.Vanda licensed Tradipitant from American drugmaker Eli Lilly and Company. It is being developed for multiple conditions, including gastroparesis, motion sickness, and the prevention of nausea and vomiting induced by GLP-1 receptor agonists.Earlier this month, the company announced that Tradipitan reduced nausea and vomiting induced by GLP-1 drug Wegovy in overweight and obese adults by about 50%. The company is looking forward to a late-stage trial for the condition in the first half of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of VNDA traded 3% higher on Friday morning. On Stocktwits, retail sentiment around VNDA stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user highlighted that the company does not expect a delay in its drug application decision.<stembedurl>https://stocktwits.com/Massimo21/message/637642514</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> is up by 14% this year and by 6% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/baidu-reportedly-begins-layoffs-in-bid-to-cut-costs-after-disappointing-quarter/cL5aTUpRELQ">Baidu Reportedly Begins Layoffs In Bid To Cut Costs After Disappointing Quarter, AI Roles Largely Safe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review 

The FDA was initially expected to complete the re-review on November 26 and has since then extended it to December 5.

<ul class="summary-bullets"><li>Barclays noted that the company matched estimates on sales and beat on earnings, driven by continued strength at Hollister, with 15% comparable sales growth.</li><li>The firm said that it sees strong momentum for Abercrombie heading into the holiday season.</li><li>Morgan Stanley on Wednesday raised the firm's price target on Abercrombie &amp; Fitch to $95 from $78 and maintained an ‘Equal Weight’ rating.</li></ul>Abercrombie &amp; Fitch was one of the top-trending tickers on Stocktwits&nbsp;on Friday&nbsp;after Barclays raised the firm's price target, noting the company's third-quarter results this week showcased the continued strength of its Hollister brand.Barclays raised its price target on Abercrombie &amp; Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly. The firm noted that the company matched estimates on sales and beat on earnings, driven by continued strength from Hollister with 15% comp salesBarclay said that it sees strong momentum for Abercrombie heading into the holiday season.<h2 class="st-heading-2">Abercrombie’s Better-Than-Expected Q3 Results</h2>On Tuesday, the company’s third-quarter net sales rose 7% to $1.29 billion, compared with Wall Street estimates of $1.28 billion, according to data from Fiscal AI. Abercrombie’s quarterly adjusted earnings per share came in at $2.36, compared with expectations of $2.17.Abercrombie also raised the lower end of its annual net sales and profit forecasts heading into the holiday season, betting on growing demand for its namesake brand and Hollister’s products.<h2 class="st-heading-2">Analysts’ Take</h2>Morgan Stanley on Wednesday raised the firm's price target on Abercrombie &amp; Fitch to $95 from $78 and maintained an ‘Equal Weight’ rating. The third-quarter beat "surprised to the upside,” and the firm leaves the report more constructive as Abercrombie’s financial profile "may be structurally better than we thought," Morgan Stanley said.UBS analysts noted that Abercrombie's results and improved guidance highlight its strong fundamentals and noted that the firm sees potential for an earnings per share (EPS) compound annual growth rate of 14% following FY25.Retail sentiment on Abercrombie remained unchanged in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/ANF">Shares of Abercrombie</a> have declined by over 36% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/from-walmart-to-best-buy-retailers-see-a-solid-start-to-holiday-quarter/cL5aGzmRELI">From Walmart To Best Buy, Retailers See A Solid Start To Holiday Quarter – But Consumers Are Waiting For Discounts</a>

General view of the Abercrombie and Fitch store in Carnaby Street.

Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum

Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly.

<ul class="summary-bullets"><li>Redemplo was approved by the FDA earlier this month, marking a milestone for Arrowhead as it becomes a commercial-stage company.</li><li>The company said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis.</li><li>Arrowhead reported revenue of $829.4 million in fiscal year 2025, compared to $3.55 million in FY24.</li></ul> Morgan Stanley on Wednesday raised its price target on Arrowhead Pharmaceuticals (ARWR) to $48 from $45 while keeping an ‘Equal Weight’ rating on the shares.Shares of the company traded 22% higher at the time of writing on Wednesday morning.According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)." Severe hypertriglyceridemia refers to a medical condition where there are dangerously high levels of triglycerides in the blood.<h2 class="st-heading-2">Significance Of Redemplo Approval</h2>Redemplo is Arrowhead’s first FDA-approved medicine. Its approval earlier this month as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome marked a milestone for Arrowhead as it evolves into a commercial-stage pharmaceutical company.Familial chylomicronemia syndrome (FCS) is a rare, genetic disorder where the body cannot properly break down fat, leading to extremely high levels of triglycerides in the blood. Arrowhead estimates that about 6,500 people in the U.S. are living with FCS.“Arrowhead is truly just getting started, and we are well-positioned to execute on our aggressive goals in discovery, clinical development, business development, and commercial to enable multiple potential new launches, both independently and with partners, over the coming years,” Arrowhead CEO Christopher Anzalone said on Tuesday.The company also said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis due to high triglyceride levels.<h2 class="st-heading-2">FY25 Earnings</h2>Arrowhead <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-reports-2025-fiscal-year-end-results/">reported</a> revenue of $829.4 million in fiscal 2025 (FY25), compared to $3.6 million in FY24, and above an analyst estimate of $757.44 million.Net loss per share came in at $0.01, down from the loss of $5 reported in FY24, and lower than an analyst estimate of a loss of $0.03 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ARWR jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume remained at 'high' levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than tripled this year and risen by about 172% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-posts-unexpected-loss-in-q3-as-ev-sales-drop/cL53uOfREWq">Li Auto Posts Unexpected Loss In Q3 As EV Sales Drop</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target

According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)."

<ul class="summary-bullets"><li>The company said its net loss for the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024.</li><li>The company is now seeking a re-examination of CHMP’s opinion on its Alzheimer’s drug, Blarcamesine.&nbsp;</li><li>It expects a cash runway of more than 3 years.</li></ul> Shares of Anavex Life Sciences Corp. (AVXL) jumped 10% on Monday afternoon after the company reported a lower-than-expected loss for the fourth quarter.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-upd">said</a> that net loss in the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024, and lower than the loss of $0.15 per share expected by analysts, according to data from Fiscal AI.The company ended the quarter with cash and cash equivalents of $102.6 million. It now expects a cash runway of more than 3 years.<h2 class="st-heading-2">Blarcamesine’s Path Forward</h2>Anavex is focused on developing treatments for neurodegenerative disorders like Alzheimer’s. “There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer’s disease,” said CEO Christopher U. Missling.Earlier this month, Anavex<a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E"> said</a> that a European Medicines Agency (EMA) committee did not recommend approval of the company’s application for its Alzheimer’s drug, Blarcamesine. The Committee for Medicinal Products for Human Use provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens the chances of EMA approval for the drug.The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion. The firm reiterated the course of action on Tuesday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that they are “cautiously optimistic” about the stock’s future.<stembedurl>https://stocktwits.com/Filldagap/message/637414773</stembedurl>AVXL stock is down 68% this year and by 63% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pmcb-stock-jumps-after-company-sells-stake-in-femasys/cL52o2lREgL">PMCB Stock Jumps 25% After Company Sells Stake In Femasys</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug

Anavex ended the quarter with cash and cash equivalents of $102.6 million.

iShares Trust - iShares Russell 2000 BuyWrite ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

IWMW
iShares Russell 2000 BuyWrite ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWMW News

IWMWiShares Russell 2000 BuyWrite ETF